While CAPE has mostly been found effective against breast cancer and nasopharyngeal carcinoma cells via targeting EGFR, it showed dose dependent inhibition of both the total and phosphorylated forms of EGFR protein expression (0–40 μM) [46]. This evidence concerns the gene EGFR and breast cancer.